Brain and skeletal muscle bioenergetic failure in familial hypobetalipoproteinaemia

Journal of Neurology Neurosurgery and Psychiatry

Volumn 62, Issue 6, 1997, Pages 574-580

  Lodi, Raffaele ^a,e   Rinaldi, Rita ^a   Gaddi, Antonio ^b   Iotti, Stefano ^a   D'Alessandro, Roberto ^a   Scoz, Nicoletta ^b   Battino, Maurizio ^c   Carelli, Valerio ^a   Azzimondi, Giuseppe ^a   Zaniol, Paolo ^d   Barbiroli, Bruno ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Dipartimento di Medicina Clinica e Biotecnologia Applicata D Campanacci   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Familial hypobetalipoproteinaemia

Indexed keywords

ADENOSINE DIPHOSPHATE; ALPHA TOCOPHEROL; APOLIPOPROTEIN B; CREATINE PHOSPHATE; LIPOPROTEIN; PHOSPHATE; UBIDECARENONE;

ADULT; ARTICLE; BIOENERGY; BRAIN; CASE REPORT; CLINICAL FEATURE; ENERGY METABOLISM; ENZYME BLOOD LEVEL; EXERCISE; FAMILIAL DISEASE; FEMALE; HUMAN; HYPOBETALIPOPROTEINEMIA; MALE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHOSPHORYLATION; PRIORITY JOURNAL; REST; SKELETAL MUSCLE; VITAMIN BLOOD LEVEL;

BRAIN; ENERGY METABOLISM; FEMALE; HUMANS; HYPOBETALIPOPROTEINEMIAS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PHOSPHOCREATINE; PHOSPHORYLATION; POINT MUTATION; UBIQUINONE; VITAMIN E;

EID: 0031010286     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.62.6.574     Document Type: Article

References (61)

1. Malloy MJ, Kane JP. Hypolipidemia. Med Clin North Am 1982;66:469-84.
2. Kane JP, Havel RJ. Familial hypobetalipoproteinemia. In: Scriver RC, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease (6th ed). USA: McGraw Hill, 1989:1151-3.
3. Mars H, Lewis LA, Robertson AL, Butkus A, Williams GH. Familial Hypo-B-lipoproteinemia. A genetic disorder of lipid metabolism with nervous system involvement. Am J Med 1969;46:866-900.
4. Traber MG, Sokol RJ, Ringel SP, Neville HE, Thellman CA, Kayden HJ. Lack of tocopherol in peripheral nerves of vitamin E-deficient patients with peripheral neuropathy. N Engl J Med 1987;317:262-5.
5. Kayden HJ, Traber MC. Absorbtion, lipoprotein transport, and regulation of plasma concentration of vitamin E in humans. J Lipid Res 1993;34:343-58.
6. Kayden HJ. The neurologic syndrome of vitamin E deficiency: a significant cause of ataxia. Neurology 1993; 43:2167-9.
7. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995;1271:195-204.
8. Forsmark-Andree P, Ernster L. Evidence for a protective effect of endogenous ubiquinol against oxidative damage to mitochondrial protein and DNA during lipid peroxidation. Mol Aspects Med 1994;15(suppl):73-81.
9. Kanno T, Utsumi T, Ide A, Takehara Y, Saibara T, Akiyama J, et al. Dysfunction of mouse liver mitochondria induced by 2,2′-azobis-(2-amidinopropane) dihydrochloride, a radical initiator, in vitro and in vivo. Free Radic Res 1994;21:223-34.
10. Kristal BS, Park BJ, Yu BP. Antioxidants reduce peroxyl-mediated inhibition of mitochondrial transcription. Free Radic Biol Med 1994;16:653-60.
11. Yen TC, King KL, Lee HC, Yeh SH, Wei YH. Age-dependent increase of mitochondrial DNA deletions together with lipid peroxides and superoxide dismutase in human liver mitochondria. Free Radic Biol Med 1994;16:207-14.
12. Shigenaga MK, Hagen T, Ames BN. Oxidative damage and mitochondrial decay in ageing. Proc Natl Acad Sci USA 1994;91:10771-8.
13. Battino M, Fato R, Parenti-Castelli G, Lenaz G. Coenzyme Q can control the efficiency of oxidative phosphorylation. Int J Tissue Reac 1990;12:137-44.
14. Descovich GC, Dormi A, Minardi A, Benassi B, Cavina A, et al. L'indagine di Brisighella. Studio dei fattori di rischio metabolici in un borgo dell'Emilia Romagna (Prima parte). Alimentazione e Dintorni, The Practitioner Edizione Italiana 1992;156(suppl):3-22.
15. Linton MF, Farese RV, Young SG. Familial hypobetalipoproteinemia. J Lipid Res 1993;34:521-41.
16. Gaddi A, Ciarrocchi A, Matteucci A, Rimondi S, Ravaglia G, Descovich G, Sirtori CR. Dietary treatment for familial hypercholesterolemia - differential effects of dietary soy protein according to the apolipoprotein E phenotypes. Am J Clin Nutr 1991;53:1191-6.
17. WHO-ERICA Research Group. The CHD risk-map of Europe. The 1st report of the WHO-ERICA project. Eur Heart J 1988;9:1-36.
18. Harding AE, Sweeney MG, Govan GG, Riordan-Eva P. Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation. Am J Hum Genet 1995;57:77-86.
19. EEC concerted research project. Quality assessment in in vivo NMR spectroscopy. Results of a concerted research project of the European Economic Community (6 papers). Magn Reson Imaging 1995;13:115-76.
20. 31P MR spectroscopy in 28 patients with mitochondrial cytopathies. J Cereb Blood Flow Metab 1993;13:469-74.
21. 13C NMR. J Magn Reson 1984;59:338-42.
22. Bottomly PA, Hardy CJ. Rapid, reliable in vivo assay of human phosphate metabolites by nuclear magnetic resonance. Clin Chem 1989;59:392-5.
23. 31P MRS. Proc Natl Acad Sci USA 1986;83:9458-62.
24. Veech RL, Lawson JWR, Cornell NW, Krebs HA. Cytosolic phosphorylation potential. J Biol Chem 1979;254: 6538-47.
25. Iotti S, Lodi R, Frassineti C, Zaniol P, Barbiroli B. In vivo assessment of mitochondrial functionality in human gastrocnemius muscle by 31P MRS. The role of pH in the evaluation of phosphocreatine and inorganic phosphate recoveries from exercise. NMR Biomed 1993;6:248-53.
26. 31P-MR spectroscopy performed routinely in a clinical environment by a whole-body imager/spectrometer. Phys Med 1992;8:87-91.
27. Taylor DJ, Styles P, Matthews PM, Arnold DL, Gadian DG, Bore PJ, Radda GK. Energetics of human muscle: exercise-induced ATP depletion. Magn Reson Med 1986; 3:44-54.
28. Arnold DL, Matthews PM, Radda GK. Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of P-31 NMR. Mag Reson Med 1984;1:307-15.
29. Kemp GJ, Taylor DJ, Radda GK. Control of phosphocreatine resynthesis during recovery from exercise in human skeletal muscle. NMR Biomed 1993;6:66-72.
30. 1H nuclear magnetic resonance studies. Neurology 1985;35:1681-8.
31. Lehmann J, Martin HL. Improved direct determination of alpha- and gamma-tocopherol in plasma and platelets in liquid chromatography, with fluorescence detection. Clin Chem 1982;28:1784-7.
32. Takada M, Ikenoya S, Yuzuriha T, Katayama K. Studies on reduced and oxidized coenzyme Q (ubiquinones). The determination of oxidation reduction levels of coenzyme Q in mitochondria, microsome and plasma by high performance liquid chromatography. Biochim Biophys 1982;679:308-14.
33. Battino M, Bargossi AM, Fiorella PL, Lenaz G. Plasma and platelet coenzyme Q10 in trained athletes. Giornale Italiano di Chimica Clinica 1990;15:347-51.
34. Barbiroli B, Iotti S, Lodi R. In vivo assessment of human skeletal muscle mitochondria respiration in health and disease. Mol Cell Biochem (in press).
35. 31P-NMR spectroscopy in the newborn. In: Guthrie RD, ed. Neonatal intensive care. New York: Churchill Livingstone, 1988: 153-79.
36. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology 1994;44:666-9.
37. 31P-magnetic resonance spectroscopy and neuropsychological study. Lancet 1995;345:1260-4.
38. Montagna P, Funicello R, Pierangeli G, Cortelli P, Lugaresi E, Zaniol P, Barbiroli B. Brain oxidative metabolism in Parkinson's disease studied by phosphorus 31 magnetic resonance spectroscopy. J Neuroimaging 1993; 3:225-8.
39. Chance B, Leigh Jr J, Clark BJ, Maris J, Kent J, Nioka S, Smith D. Control of oxidative metabolism and oxygen delivery in human skeletal muscle: a steady state analysis of the work/energy cost transfer function. Proc Natl Acad Sci USA 1985;82:8384-8.
40. Matthews PM, Allaire C, Shoubridge EA, Karpati G, Carpenter S, Arnold DL. In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology 1991;41:114-20.
41. 31P-magnetic resonance spectroscopy in NARP syndrome. J Neurol Neurosurg Psychiatry 1994;57:1492-6.
42. Taylor DJ, Kemp GJ, Woods CG, Edwards JH, Radda GK. Skeletal muscle bioenergetics in myotonic dystrophy. J Neurol Sci 1993;116:193-200.
43. 31P MRS of abnormal mitochondrial oxidative in skeletal muscle during recovery from exercise. NMR Biomed 1993;6:302-10.
44. Kemp GJ, Taylor DJ, Styles P, Radda GK. The production, buffering and efflux of protons in human skeletal muscle during exercise and recovery. NMR Biomed 1993;6:73-83.
45. Muller DPR, Lloyd JK, Wolff OH. Vitamin E and neurological function. Lancet 1983;i:225-8.
46. 31P-NMR spectroscopy of skeletal muscle in Becker dystrophy and DMD/BMD carriers. Altered rate of phosphate transport. J Neurol Sci 1992;109:188-95.
47. 31P-NMR study of muscle exercise metabolism in mdx mice: evidence for abnormal pH regulation. J Neurol Sci 1992;113:108-13.
48. Elias E, Muller DPR, Scott J. Association of spinocerebellar disorders with cystic fibrosis or chronic childhood cholestasis and very low serum vitamin E. Lancet 1981; ii:1319-21.
49. Rosenblum JL, Keating JP, Presky AL, Nelson JS. A progressive neurologic syndrome in children with chronic liver disease. N Engl J Med 1981;304:503-8.
50. Howard L, Ovesen L, Satya-Murti S, Chu R. Reversible neurological symptoms caused by vitamin E deficiency in a patient with short bowel syndrome. Am J Clin Nutr 1982;36:1243-9.
51. Gotoda T, Arita M, Arai H, Inoue K, Yokota T, Fukuo Y, et al. Adult-onset spinocerebellar dysfunction caused by a mutation in the gene for the a-tocopherol-transfer protein. N Engl J Med 1995;333:1313-8.
52. 10 as a protective agent against radical formation in man. In: Benzi G, ed. Advances in myochemistry. London: John Libbey Eurotext, 1987:305-18.
53. 10 in health and disease. In: Lenaz G, ed: Highlights in ubiquinone research. London: Taylor and Francis, 1990:288-95.
54. Appelkvist EL, Aberg F, Guan Z, Parmryd I, Dallner G. Regulation of coenzyme Q biosynthesis. Molec Aspects Med 1994;15(suppl):37-46.
55. Ogasahara S, Yorifuji S, Nishikawa Y, Takahashi M, Wada K, Hazama T, et al. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology 1985; 35:372-7.
56. 31P NMR study. Neurology 1989; 39:399-403.
57. 10 treatment in retinitis pigmentosa. Molec Aspects Med 1994;15(suppl):221-30.
58. Ogasahara S, Engel A, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci USA 1989;86: 2379-82.
59. DiMauro S, Moraes CT. Mitochondrial encephalomyopathies. Arch Neurol 1993;50:1197-208.
60. Eleff S, Barker P, Blackband S, Chatham J, Lutz M, Johns D, Bryan R. Phosphorus magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels phosphocreatine. Ann Neurol 1990;27:626-30.
61. Descovich GC, Dormi A, Minardi A, Benassi B, Bonetti C, Ceredi C, et al. L'indagine di Brisighella. Studio dei fattori di rischio metabolici in un borgo dell'Emilia Romagna (seconda parte). Alimentazione e Dintorni, The Practitioner Edizione Italiana 1992;167(suppl):3-22.